Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use

[1] Craig WA(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-10

[2] Eagle H(1950)Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels Am J Med 9 280-299

[3] Fleischman R(2004)Antimicrobial pharmacodynamics: critical interactions of “bug and drug” Nat Rev Microbiol 2 289-300

[4] Musselman AD(1988)Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model J Infect Dis 158 831-847

[5] Drusano GL(2008)Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 345-351

[6] Vogelman B(2012)Continuous infusion of antibiotics in the critically ill: the new holy grail for beta-lactams and vancomycin Ann Intensive Care. 2 22-104

[7] Gudmundsson S(2012)Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics Minerva Anestesiol 78 94-606

[8] Leggett J(2005)Continuous infusion of beta-lactams Curr Opin Crit Care 13 598-213

[9] Turnidge J(2005)Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model J Antimicrob Chemother 55 209-1801

[10] Ebert S(1995)Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model Antimicrob Agents Chemother 39 1797-15

[1] Craig WA(1998)Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men Clin Infect Dis 26 1-10

[2] Eagle H(1950)Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels Am J Med 9 280-299

[3] Fleischman R(2004)Antimicrobial pharmacodynamics: critical interactions of “bug and drug” Nat Rev Microbiol 2 289-300

[4] Musselman AD(1988)Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model J Infect Dis 158 831-847

[5] Drusano GL(2008)Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 345-351

[6] Vogelman B(2012)Continuous infusion of antibiotics in the critically ill: the new holy grail for beta-lactams and vancomycin Ann Intensive Care. 2 22-104

[7] Gudmundsson S(2012)Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics Minerva Anestesiol 78 94-606

[8] Leggett J(2005)Continuous infusion of beta-lactams Curr Opin Crit Care 13 598-213

[9] Turnidge J(2005)Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model J Antimicrob Chemother 55 209-1801

[10] Ebert S(1995)Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model Antimicrob Agents Chemother 39 1797-15